{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T01:14:50Z","timestamp":1778030090831,"version":"3.51.4"},"reference-count":18,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2003,9,17]],"date-time":"2003-09-17T00:00:00Z","timestamp":1063756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2003,10]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold><jats:bold> Introduction:<\/jats:bold> Post\u2010transplant lymphoproliferative disorders (PTLD) is a consequence of Epstein\u2013Barr virus (EBV) infection and is a B\u2010cell hyperplasia with CD\u201020 positive lymphocytes. The treatment of PTLD includes reduction\/withdrawal of immunosuppression and chemotherapy. This study reports our center experience with humanized monoclonal antibody against CD\u201020 (Rituximab) for the treatment of PTLD.<\/jats:p><jats:p><jats:bold>Material and methods:<\/jats:bold> Eight cases of PTLD after solid organ transplantation [six kidney, one kidney\/pancreas (KP) and one liver] occurred between September 1998 and October 2001. The mean time between transplant and the diagnosis of PTLD was 57.3\u2003months (range 3\u2003months to 10\u2003yr). Five patients underwent cadaveric transplant, five males and six were Caucasians with mean age of 48\u2003yr (range 20\u201367\u2003yr).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The clinical presentation was as follows: lymphadenopathy\u20105, gastrointestinal bleeding\u20102 and tonsillar enlargement\u20101. The diagnosis was made by a lymph node biopsy in five, a gastric ulcer biopsy in two and a tonsillar biopsy in one case. Six of them had polymorphous, two had monoclonal B\u2010cell lymphoma, and all were positive for CD\u201020. Six were related to EBV, documented by latent membrane protein (LMP) or Epstein\u2013Barr encoded RNA (EBER) staining. Immunosuppression at the time of PTLD diagnosis consisted of tacrolimus in six cases and cyclosporine A (CsA) in two with mycophenolate mofetil (MMF) and azathioprine\u20103 each and sirolimus\u20101. Rituximab was administered at a dose of 375\u2003mg\/m<jats:sup>2<\/jats:sup> once a week for 4\u2003wk. There were no side effects seen with this therapy. Immunosuppression was reduced in all patients. Complete remission was observed in seven cases (one required two courses). One patient who did not respond received chemotherapy. Patients were followed for a mean period of 22.5\u2003months (range 10\u201345\u2003months post\u2010PTLD diagnosis. At the last follow\u2010up all eight patients were alive, seven with a functioning graft and one on maintenance dialysis. Three of these patients had been in remission for more than 2.5\u2003yr.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Rituximab is an effective agent in the treatment of PTLD without the morbidity characteristic of chemotherapy. Chemotherapy should be reserved only for those refractory to Rituximab therapy.<\/jats:p>","DOI":"10.1034\/j.1399-0012.2003.00054.x","type":"journal-article","created":{"date-parts":[[2003,9,17]],"date-time":"2003-09-17T08:32:23Z","timestamp":1063787543000},"page":"417-422","source":"Crossref","is-referenced-by-count":73,"title":["Humanized anti\u2010CD20 monoclonal antibody (Rituximab) treatment for post\u2010transplant lymphoproliferative disorder*"],"prefix":"10.1111","volume":"17","author":[{"given":"Vasundhara","family":"Ganne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nauman","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bal","family":"Kamaplath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chung\u2010Che","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric P","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A","family":"Bresnahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundaram","family":"Hariharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,9,17]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)90994-2"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199912270-00006"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-198505000-00001"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199012203232510"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90279-9"},{"key":"e_1_2_9_7_2","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549.417k32_1549_1555","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein\u2010Barr virus induced lymphoma in allogeneic transplant recipients","volume":"92","author":"Rooney CM","year":"1998","journal-title":"Blood"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105233242102"},{"key":"e_1_2_9_9_2","first-page":"S55","article-title":"Monoclonal antibodies in the treatment of non\u2010Hodgkin's lymphoma: Recent results, future and prospects","volume":"2","author":"Renner C","year":"1997","journal-title":"Leukemia"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199308123290703"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V71.5.1234.1234"},{"key":"e_1_2_9_12_2","first-page":"214","article-title":"Pre\u2010transplantation sero\u2010negative Epstein\u2010Barr virus status is the primary risk factor for post\u2010transplantation lymphoproliferative disorder in adult heart, lung and other solid organ transplantation","volume":"14","author":"Walker RC","year":"1995","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_9_13_2","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJM199012203232502","article-title":"Increased incidence of lymphoproliferative disorder after immunosuppression with monoclonal antibody OKT3 in cardiac transplant recipients","volume":"323","author":"Swinnen LJ","journal-title":"N Engl J Med"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.ndt.a027077"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/20.5.1346"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/514142"},{"key":"e_1_2_9_17_2","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1182\/blood.V92.9.3137","article-title":"Anti\u2010B cell monoclonal treatment of severe post\u2010transplant B lymphoproliferative disorder: prognostic factor and long\u2010term outcome","volume":"92","author":"Benkerrou M","year":"1998","journal-title":"Blood"},{"key":"e_1_2_9_18_2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/11.suppl_1.S113","article-title":"Humanized anti\u2010CD20 monoclonal antibody (Rituximab) in post\u2010transplant B lymphoproliferative disorder: A retrospective analysis in 32 patients","volume":"11","author":"Miliped N","year":"2000","journal-title":"Ann Oncol"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200002150-00021"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-0012.2003.00054.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-0012.2003.00054.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1399-0012.2003.00054.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T22:37:13Z","timestamp":1697236633000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1399-0012.2003.00054.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9,17]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,10]]}},"alternative-id":["10.1034\/j.1399-0012.2003.00054.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1399-0012.2003.00054.x","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9,17]]}}}